Quarterly Report, Q1-Q3 2013 for Spar Nord Bank A/S •

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Quarterly Report, Q1-Q3 2013 for Spar Nord Bank A/S

• Core income grew 15% compared with Q1-Q3 2012, climbing to DKK 2,067 million: Net interest income grew 17% and net income from fees, charges and commissions 27%, driven by a greater volume and a higher activity level.

• Costs totalled DKK 1,225 million - 14% up on the same period 2012, but lower than expected after Sparbank’s activities were integrated into Spar Nord in Q4 2012.

• Core earnings before impairment amounted to DKK 841 million, equal to a 16% growth.

• Loan impairment losses totalled DKK 305 million, corresponding to an impairment ratio of 0.95% p.a.

• In Q3 bank lending stabilized at DKK 34.1 billion - continued major capital inflow into pooled schemes and mandate-based investment products resulted in a drop in bank deposits of DKK 0.4 billion to DKK 42.0 billion.

• The Common Equity (Tier 1) ratio was 14.0% (end-2012: 12.1%). The overall solvency ratio

came to 17.4% (end-2012: 15.5%), while the solvency need ratio was 10.1% (end-2012: 10.0%), corresponding to an excess coverage of DKK 3.2 billion.

• The projection of core earnings before impairment of DKK 1,000 - 1,100 million for the full year is maintained, and the projected impairment ratio for the year is maintained at a level of 1.0%.

• Together with the quarterly financial statements, the dividend policy is presented: The future dividend level (2014- ) has been fixed at 33% of the net profits for the year.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 24

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 18

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 21

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 27

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

Boussard & Gavaudan's NAV Report Highlights for Investors

Updated Category News Views 72

Boussard & Gavaudan Holding Limited: NAV Update Boussard & Gavaudan Holding Limited is pleased to provide a recent update regarding the company's net asset values (NAV) for its Ordinary Shares. Investors are encouraged to stay informed about the performance and returns associated with their investments. Current NAV Estimates The estimated NAV, as of the close of business,...

Continue Reading
Moab Launches Free Shuttle to Enhance Park Access

Updated Category News Views 11

Moab's Shuttle: A New Era for Park Access A breeze of change is sweeping through the dusty trails of Moab, Utah, and this isn't just any switch—it's about making the always-packed Arches National Park a bit less of a traffic nightmare. Imagine this: strolling up to a shuttle, no tickets, no cash needed, and you're off to see epic scenery like The Windows and Delicate...

Continue Reading
Grid Dynamics Shares Upcoming Financial Results Preview

Updated Category News Views 82

Overview of Upcoming Financial Results Announcement Grid Dynamics Holdings, Inc. (Nasdaq: GDYN), recognized as a frontrunner in the digital transformation sector, is preparing to announce its financial results for the fourth quarter and full year of the fiscal year 2024. This much-anticipated event is scheduled for February 20, 2025. Investors and stakeholders can look...

Continue Reading
BioSig Technologies and Streamex Successfully Close $15 Million Offering

Updated Category News Views 154

BioSig Technologies and Streamex Close $15 Million Offering BioSig Technologies, Inc. is excited to share that it has successfully completed a public offering, raising approximately $15 million. The company, now merged with Streamex Exchange Corporation (NASDAQ: BSGM), focuses on gold tokenization infrastructure, positioning itself as a leader in the industry. Details of...

Continue Reading
Navigate Wellbeing Solutions Achieves 2024 Workplace Excellence

Updated Category News Views 64

Navigating Towards Employee Satisfaction Navigate Wellbeing Solutions has proudly secured the Great Place To Work Certification™ for the year 2024. This recognition is a testament to the positive work environment fostered by the organization, as revealed by feedback from employees. An impressive 92% of team members agree it's a great place to work, significantly above...

Continue Reading